A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: U3 1402|DRUG: U3 1402
Sponsor: SOLTI Breast Cancer Research Group
Collaborators: Daiichi Sankyo